BofA analyst Derik de Bruin lowered the firm’s price target on NeoGenomics (NEO) to $16 from $19 and keeps a Neutral rating on the shares. Soft Q4 sales led to a 14% stock pullback, though management is confident this miss is only temporary, particularly given the impact of a softer Pharma budget flush, says BofA, which tweaks estimates after the report.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Achieves Double-Digit Revenue Growth in 2024
- NeoGenomics Q4 Earnings Call Highlights Growth Amid Challenges
- NeoGenomics: Overcoming Short-term Setbacks with Strategic Growth Initiatives and Leadership Transition
- Buy Rating Maintained for NeoGenomics Despite Mixed Results and Leadership Changes
- Delta flight crashes in Toronto, Southwest cuts corporate roles: Morning Buzz